Suchergebnisse - "Kshirsagar, Smita"

PubPharm (32)

1

The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor

enthalten in: Drug metabolism and disposition: the biological fate of chemicals | 2023

von Takahashi, R. | Malhi, V. | Liederer, B. | +10

2

A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers

enthalten in: Clinical and translational science | 2023

von Jones, N. | Kshirsagar, S. | Mohanan, V. | +11

3

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients

enthalten in: Clinical pharmacokinetics | 2021

von Verrest, L. | Wasunna, M. | Kokwaro, G. | +19

4

Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

enthalten in: Clinical pharmacology in drug development | 2021

von Felip, E. | Burotto, M. | Zvirbule, Z. | +12

CommentIn: Clin Pharmacol Drug Dev. 2022 Jan;11(1):134-135. - PMID 34951144

5

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients

enthalten in: Clinical pharmacokinetics | 2021

von Verrest, L. | Wasunna, M. | Kokwaro, G. | +19

6

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients

enthalten in: Clinical pharmacokinetics | 2021

von Verrest, L. | Wasunna, M. | Kokwaro, G. | +19

7

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients

enthalten in: Clinical pharmacokinetics | 2021

von Verrest, L. | Wasunna, M. | Kokwaro, G. | +19

8

Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer

enthalten in: Clinical Pharmacology in Drug Development | 2021

von Felip, E. | Burotto, M. | Zvirbule, Z. | +12

9

Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia : Results from the Phase III MURANO Study

enthalten in: Clinical pharmacokinetics | 2019

von Deng, R. | Gibiansky, L. | Lu, T. | +15

10

Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study

enthalten in: Clinical pharmacokinetics | 2019

von Deng, R. | Gibiansky, L. | Lu, T. | +15